Eli Lilly's Mounjaro Outperforms Novo Nordisk's Ozempic in Weight Loss Study

New research indicates Mounjaro leads to greater and faster weight reduction than Ozempic, with similar side effect profiles.

Study analyzed health records of over 18,000 adults using tirzepatide (Mounjaro) or semaglutide (Ozempic).
Mounjaro users lost an average of 15.3% of their body weight over 12 months, compared to 8.3% for Ozempic users.
Patients on Mounjaro were three times more likely to achieve a 15% weight loss than those on Ozempic.
Both drugs showed similar rates of gastrointestinal side effects, including nausea and vomiting.
Further research is needed to compare other health outcomes like cardiovascular benefits.